HK1061817A1 - Use of flumazenil to produce a medicament for the treatment of cocaine dependency - Google Patents

Use of flumazenil to produce a medicament for the treatment of cocaine dependency

Info

Publication number
HK1061817A1
HK1061817A1 HK04104788A HK04104788A HK1061817A1 HK 1061817 A1 HK1061817 A1 HK 1061817A1 HK 04104788 A HK04104788 A HK 04104788A HK 04104788 A HK04104788 A HK 04104788A HK 1061817 A1 HK1061817 A1 HK 1061817A1
Authority
HK
Hong Kong
Prior art keywords
flumazenil
treatment
medicament
produce
cocaine dependency
Prior art date
Application number
HK04104788A
Other languages
English (en)
Inventor
Juan Jose Legarda Ibanez
Original Assignee
Hythiam Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hythiam Inc filed Critical Hythiam Inc
Publication of HK1061817A1 publication Critical patent/HK1061817A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
HK04104788A 2001-02-15 2004-07-03 Use of flumazenil to produce a medicament for the treatment of cocaine dependency HK1061817A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200100342 2001-02-15
PCT/ES2002/000061 WO2002064213A1 (fr) 2001-02-15 2002-02-08 Utilisation de flumazenil dans l'elaboration d'un medicament destine au traitement de la dependance a la cocaine

Publications (1)

Publication Number Publication Date
HK1061817A1 true HK1061817A1 (en) 2004-10-08

Family

ID=8496743

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04104788A HK1061817A1 (en) 2001-02-15 2004-07-03 Use of flumazenil to produce a medicament for the treatment of cocaine dependency

Country Status (21)

Country Link
US (2) US7186711B2 (fr)
EP (1) EP1378267B1 (fr)
JP (2) JP4272885B2 (fr)
KR (1) KR100712571B1 (fr)
CN (1) CN1327843C (fr)
AT (1) ATE363923T1 (fr)
AU (1) AU2002231811B2 (fr)
BR (1) BR0207866A (fr)
CA (1) CA2436511C (fr)
CY (1) CY1106845T1 (fr)
DE (1) DE60220512T2 (fr)
DK (1) DK1378267T3 (fr)
ES (1) ES2287255T3 (fr)
HK (1) HK1061817A1 (fr)
IL (1) IL157144A0 (fr)
MX (1) MXPA03007281A (fr)
NZ (1) NZ528164A (fr)
PT (1) PT1378267E (fr)
RU (1) RU2322985C2 (fr)
UA (1) UA79586C2 (fr)
WO (1) WO2002064213A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192271A1 (en) 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
CN1327843C (zh) 2001-02-15 2007-07-25 海萨姆有限公司 氟马西尼在用于可卡因依赖治疗药物制备中的应用
AU2006235318A1 (en) 2005-04-07 2006-10-19 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence
US7855196B2 (en) 2005-08-22 2010-12-21 Pierre Mainville Composition comprising a benzodiazepine agonist and a benzodiazepine antagonist
ES2289935B1 (es) * 2006-07-14 2008-12-16 Juan Jose Legarda Ibañez Empleo de flumazenilo en la elaboracion de un medicamento para el tratamiento de la patologia depresiva.
US20110034442A1 (en) * 2007-08-08 2011-02-10 Jaun Jose Legarda Ibanez Use and Methods of Use for an Antagonist of the Serotin3 Receptor (5-HT3) and a Selective Modulator of Chloride Channels for the Treatment of Addiction to or Dependence on Medicines/Drugs or Nervous System Disorders
US9396280B2 (en) * 2008-06-23 2016-07-19 Microsoft Technology Licensing, Llc Command driven web site browsing
CA2827336C (fr) 2011-02-23 2016-01-26 Coeruleus Ltd. Complexes de flumazenil, compositions les comprenant et leurs utilisations
US9308616B2 (en) 2013-01-21 2016-04-12 Innovative Finishes LLC Refurbished component, electronic device including the same, and method of refurbishing a component of an electronic device
EP3057596A4 (fr) * 2013-10-14 2017-03-29 Palmaya Pty Ltd Compositions et procédés pour les administrer
CN107115359A (zh) * 2016-02-24 2017-09-01 郑恩哲 阻断海洛因或吗啡毒品中毒路径的点滴处方及其应用
AU2018310881C1 (en) 2017-07-31 2021-12-16 Novartis Ag Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028611A (en) * 1989-06-29 1991-07-02 The Regents Of The University Of Minnesota Treatment for cocaine use
US5229120A (en) * 1992-02-05 1993-07-20 Devincent James F Treatment for cocaine abuse
GB9420010D0 (en) 1994-10-01 1994-11-16 Marck Sharp & Dohme Limited Nucleic acids
US6174882B1 (en) * 1998-11-23 2001-01-16 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
EP1125579A3 (fr) * 2000-01-18 2003-01-02 Pfizer Products Inc. Utilisations de composés modulant la liaison entre l'AGRP et les récepteurs à la mélanocortine
CN1327843C (zh) * 2001-02-15 2007-07-25 海萨姆有限公司 氟马西尼在用于可卡因依赖治疗药物制备中的应用
US6740677B2 (en) 2002-08-19 2004-05-25 Hong Xue Methods of treating benzodiazepine site (BZD-S) associated syndromes using 2′ hydroxyflavonoids

Also Published As

Publication number Publication date
US20060122219A1 (en) 2006-06-08
CA2436511A1 (fr) 2002-08-22
WO2002064213A1 (fr) 2002-08-22
AU2002231811B2 (en) 2006-02-16
ATE363923T1 (de) 2007-06-15
NZ528164A (en) 2006-03-31
US20070142364A1 (en) 2007-06-21
DK1378267T3 (da) 2007-10-08
DE60220512T2 (de) 2008-02-07
KR20040010592A (ko) 2004-01-31
JP4272885B2 (ja) 2009-06-03
JP2004521904A (ja) 2004-07-22
KR100712571B1 (ko) 2007-05-02
EP1378267B1 (fr) 2007-06-06
DE60220512D1 (de) 2007-07-19
MXPA03007281A (es) 2005-01-25
IL157144A0 (en) 2004-02-08
JP2008201799A (ja) 2008-09-04
CA2436511C (fr) 2009-08-04
RU2322985C2 (ru) 2008-04-27
CN1327843C (zh) 2007-07-25
UA79586C2 (en) 2007-07-10
PT1378267E (pt) 2007-09-11
CY1106845T1 (el) 2012-05-23
EP1378267A1 (fr) 2004-01-07
ES2287255T3 (es) 2007-12-16
RU2003127718A (ru) 2005-01-27
BR0207866A (pt) 2004-03-23
CN1491125A (zh) 2004-04-21
US7186711B2 (en) 2007-03-06

Similar Documents

Publication Publication Date Title
YU71901A (sh) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
IL196301A0 (en) Medicament for the treatment of hapatitis c
HUP0402661A3 (en) Formulation and dosage form for the controlled delivery of therapeutic agents
EE05404B1 (et) Kinuklidiini derivaat, selle saamine ja kasutamine ravimi valmistamiseks, mis on ette n„htud respiratoorsete, kuseelundite v?i mao-soolte haiguste ravimiseks, ning seda sisaldav ravimkompositsioon
HK1080361A1 (en) The use of compound in the preparation of medicaments for treating demyelinating diseases
NO324227B1 (no) Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer
EP1404343A4 (fr) Combinaisons therapeutiques pour le traitement des carences hormonales
EE05301B1 (et) Meetod epotilooni analooge sisaldavate ravimvormide valmistamiseks ning nende kasutamine ravimi valmistamiseks
CY1106845T1 (el) Χρηση της φλουμαζενιλης για την παρασκευη ενος φαρμακου για την αγωγη της εξαρτησεως απο την κοκαϊνη
GB2414183B (en) Delivery of nitric oxide for therapeutic treatment
IL156798A0 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependency
EP1631297A4 (fr) Traitement des maladies a mediation immunologique au moyen de composes a base de vitamine d active, seuls ou en association avec d'autres agents therapeutiques
NO20042208L (no) Vaginalt administrerte anti-dysrytmiske midler for behandling av bekkensmerter
HK1068106A1 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
GB0004531D0 (en) The treatment of respiratory diseases
HRP20020893A2 (en) Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
AU2002231811A1 (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
IL147188A (en) Use of il6ril6 chimera in the manufacture of a remedy for neurological diseases
HUP0300876A3 (en) Use of diclofenac for the manufacture of medicament for the topical treatment of burns
HRP20050281A2 (en) Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes
GB9910197D0 (en) Multivalent agents for use in the treatment of mitochondrial diseases
SI1285659T1 (sl) Uporaba klaritromicinskih sestavkov za pripravo zdravila za zdravljenje deformirajocega artritisa

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140208